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Abstract
Background: Recent evidence indicates that gene variants related to carotenoid metabolism play a role in the uptake of
macular pigments lutein (L) and zeaxanthin (Z). Moreover, these pigments are proposed to reduce the risk for advanced
age-related macular degeneration (AMD). This study provides the initial examination of the relationship between the gene
variants related to carotenoid metabolism, macular pigment optical density (MPOD) and their combined expression in
healthy humans and patients with AMD.
Participants and Methods: Forty-four participants were enrolled from a general population and a private practice including
20 healthy participants and 24 patients with advanced (neovascular) AMD. Participants were genotyped for the three single
nucleotide polymorphisms (SNPs) upstream from BCMO1, rs11645428, rs6420424 and rs6564851 that have been shown to
either up or down regulate beta-carotene conversion efficiency in the plasma. MPOD was determined by heterochromatic
flicker photometry.
Results: Healthy participants with the rs11645428 GG genotype, rs6420424 AA genotype and rs6564851 GG genotype all
had on average significantly lower MPOD compared to those with the other genotypes (p,0.01 for all three comparisons).
When combining BCMO1 genotypes reported to have ‘‘high’’ (rs11645428 AA/rs6420424 GG/rs6564851 TT) and ‘‘low’’
(rs11645428 GG/rs6420424 AA/rs6564851 GG) beta-carotene conversion efficiency, we demonstrate clear differences in
MPOD values (p,0.01). In patients with AMD there were no significant differences in MPOD for any of the three BCMO1
gene variants.
Conclusion: In healthy participants MPOD levels can be related to high and low beta-carotene conversion BCMO1
genotypes. Such relationships were not found in patients with advanced neovascular AMD, indicative of additional
processes influencing carotenoid uptake, possibly related to other AMD susceptibility genes. Our findings indicate that
specific BCMO1 SNPs should be determined when assessing the effects of carotenoid supplementation on macular pigment
and that their expression may be influenced by retinal disease.
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Introduction
Macular pigment carotenoids lutein (L), zeaxanthin (Z) and
meso-zeaxanthin (MZ) have numerous proposed roles within the
eye and brain. These include protection from photochemical
damage and oxidative stress [1] and improving visual and
cognitive function [2,3,4,5,6,7,8,9]. A standard clinical protocol
for measuring macular pigment optical density (MPOD) using
heterochromatic flicker photometry (HFP) has been developed
[10]. Dietary and supplementary L and Z intake correlates with
serum levels [11,12,13] and macular pigment optical density
(MPOD) in humans [14,15,16,17,18]. While factors such as
gender [19], age [20,21,22], iris colour [23], smoking habits [21]
and hereditability [24,25] have been proposed to modulate
macular pigment, genetic variants coding for proteins related to
carotenoid metabolism have been linked with macular pigment
deposition [26,27,28].
It is believed that macular pigments protect from the
development of advanced age-related macular degeneration
(AMD) with studies showing that AMD patients have lower
MPOD compared to healthy participants [29,30,31,32]. These
findings gave rise to numerous studies that aimed to determine the
effect of L and Z supplementation on AMD progression with
varying results [8,15,33,34,35,36,37]. One of the largest studies
was the Age-Related Eye Disease Study (AREDS2) [34] that
demonstrated no beneficial or harmful effect of L and Z
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supplementation. However, participants in the quintile with the
lowest dietary intake of macular carotenoids had less progression
to advanced AMD compared to those who had higher dietary
intake when supplementing with the AREDS formula (Vitamin A,
E, C beta-carotene, copper and zinc) and L and Z. A potential
unknown of the study design was identified as being the effect of
simultaneous administration of beta-carotene and L and Z, hence
potential competitive absorption of carotenoids [38]. Kostic et al.
[38] demonstrated that when lutein and beta-carotene are ingested
together, serum peak concentration of lutein is lower in the
presence of beta-carotene. Borel et al. [27] further proposed that
the enzyme beta-carotene monooxygenase (BCMO1) that regulates
the conversion from beta-carotene to Vitamin A, may also
modulate macular pigment deposition. The conversion activity
of BCMO1 is genetically determined and there is evidence that
genotype variants upstream from the BCMO1 gene affect
conversion efficiency [39]. Lietz et al. [39] highlight the impor-
tance of genotyping exonic, intronic and intergenic BCMO1 SNPs
to investigate beta-carotene conversion efficiency. In particular,
genotypes for three BCMO1 SNPs (rs11645428, rs6420424 and
rs6564851) have been identified, with decreased (rs11645428 GG,
rs6420424 AA, rs6564851 GG) and increased (rs11645428 AA,
rs6420424 GG, rs6564851 TT) beta-carotene conversion efficien-
cy but the relationship with macular pigment levels was not
evaluated in that study [39]. A large observational study
demonstrated a strong association between MPOD and the
BCMO1 SNP (rs11645428) in a healthy cohort of postmenopausal
women [26]. Another recent study confirmed these findings but
found the strongest association between MPOD and the BCMO1
SNP rs6564851 [28]. However, this study did not show an
association between BCMO1 variants and macular pigment levels
after L and Z supplementation. Neither study investigated the
combined effect of all three BCMO1 SNPs (rs11645428, rs6420424
and rs6564851) that may act synergistically to alter the catalytic
activity of BCMO1 and consequently alter pigment deposition in
the macula. Moreover, these studies were performed in healthy
participants and BCMO1 effects may not only vary in different
populations [39] but also with retinal disease.
The aim of this study was therefore to determine the
relationship between MPOD and three SNPs (rs11645428 and
rs6420424, rs6564851) upstream from the BCMO1 gene. Our
hypothesis is that participants with ‘‘high’’ and ‘‘low’’ b-carotene
conversion genotypes will have high and low MPOD levels,
respectively. We investigated a group of healthy participants and
patients with advanced neovascular macular degeneration. The
reason for including the latter group was to determine whether
BCMO1 gene variants are also associated with disease progression.
Our hypothesis is that given participants have already developed
advanced AMD, the BCMO1 SNPs will impact less on MPOD as
other environmental and genetic factors may dominate.
Methods
Ethics Statement
The Queensland University of Technology (QUT) Human
Research Ethics Committee approved this study. The study was
conducted in accordance with the guidelines of the QUT Human
Research Ethics Committee and the tenets of the Declaration of
Helsinki. Written informed consent was obtained from each
participant.
Participants
In total, 44 participants were recruited from a general
population (healthy participants with no eye disease) and a private
practice (patients with age-related macular degeneration) and
tested for macular pigment optical density (MPOD). All partici-
pants were of European ancestry except for two AMD patients
who were of Asian ancestry. Participants were genotyped for the
SNPs rs11645428, rs6420424 and rs6564851 upstream of the
BCMO1 gene. Of the 44 patients, 20 participants were assigned to
the healthy group (mean age 5665 yrs, 8 female and 12 male).
The healthy participants had best corrected visual acuities of
greater than 1.0, normal intraocular pressure (,21 mmHg), no
signs of anterior segment or retinal or optic nerve disease and
normal central retinal thickness within reported normative values
as assessed with optical coherence tomography (OCT, Stratus,
Zeiss, Germany). Twenty-four participants were assigned to the
patient group with neovascular AMD (mean age 8067 yrs, 14
female and 10 male). All AMD patients had steady fixation and
Table 1. Genotype and allele frequencies of the BCMO1 SNPs
rs11645428, rs6420424 and rs6564851 and mean MPOD.
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Group SNP and MPOD GG GA AA
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most of them had a visual acuity of greater than 0.3 (20/50) as
suggested by the MPOD manufacturer. Those participants who
had a visual acuity less than 0.3 (n = 3) were still able to fixate and
perform the MPOD successfully as has been previously demon-
strated in patients with reduced visual acuity in AMD [29,40]. All
the AMD patients were classified as AREDS level 4b [41] and
were undergoing intravitreal injection with anti-vascular endothe-
lial growth factor (anti-VEGF) treatment according to established
procedures [42]. None of the participants were taking supplements
containing either lutein or zeaxanthin at the time of the study, and
none were current smokers.
Macular Pigment Optical Density (MPOD) Determination
Macular Pigment Optical Density and ophthalmic routine
assessment (visual acuity, indirect ophthalmoscopy, intraocular
pressure and OCT) were performed by the same investigators
(ophthalmologists BF, AK and optometry staff who were blind to
the genotypes of each participant). Macular pigment optical
density was determined by heterochromatic flicker photometry
(Macular Metrics II, LLC, Providence, USA) with a 0.5u stimulus
presented in the fovea and a 2u stimulus presented at 7u in the
paracentral area [43]. The stimulus consisted of a flickering light
that alternates between a 460 nm light that is maximally absorbed
by macular pigment, and a 564 nm light that is not absorbed by
macular pigment. All participants performed four measurements
at both retinal locations. The flicker frequency was adjusted
individually before starting the test. The amount of 460 nm light
required to achieve minimum flicker (iso-luminance between the
blue and green stimuli) is used to calculate a participant’s MPOD
(in density units, D.U.) which is the log ratio of the amount of blue
light absorbed centrally to that absorbed peripherally. Patients in
the AMD group performed another four measurements at both
retinal locations at a second visit (within 3 months of treatment).
Figure 1. MPOD as a function of BCMO1 rs11645428 (error bars
indicate+SD). Healthy participants with the GG genotype show on
average significantly lower MPOD compared to those with the AA
genotype. There were no significant differences between genotypes in
the AMD group.
doi:10.1371/journal.pone.0089069.g001
Figure 2. MPOD as a function of BCMO1 rs6420424 (error bars
indicate+SD). Healthy participants with the GG genotype show on
average significantly higher MPOD compared to those with the AA
genotype. There were no significant differences between genotypes in
the AMD group.
doi:10.1371/journal.pone.0089069.g002
Figure 3. MPOD as a function of BCMO1 rs6564851 (error bars
indicate+SD). Healthy participants with the TT genotype show on
average significantly higher MPOD compared to those with the GG
genotype. There were no significant differences between genotypes in
the AMD group.
doi:10.1371/journal.pone.0089069.g003
Figure 4. MPOD as a function of ‘‘high conversion’’ (high)
(rs11645428 AA/rs6420424 GG/rs6564851 TT), ‘‘low conver-
sion’’ (low) (rs11645425 GG/rs6420424 AA/rs6564851 GG) and
‘‘medium conversion’’ (medium) (rs11645425/rs6420424/
rs6564851 remaining genotypes) triple genotypes (error bars
indicate+SD). Healthy participants with the ‘‘high conversion’’
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Genotyping
The DNA was extracted from saliva samples (Oragene DNA
self-collection kit, DNA Genotek Inc, Ottawa, Ontario, Canada)
according to established procedures used previously in our
laboratories [44,45]. DNA was then genotyped for the SNPs
rs11645428, rs6420424 and rs6564851 commercially at the
Australian Genome Research Facility (AGRF) using the Seque-
nom MassARRAY genotyping system.
Statistical Analysis
Data were analysed with a statistical package (IBM SPSS
Statistics 21). Comparisons between MPOD levels and genotypes
were made using one-way ANOVA and post-hoc analysis.
Results
Initial data screening indicated the data were normally
distributed. Forty-three out of 44 participants were successfully
genotyped for rs11645428 and rs6564851 and all 44 participants
were genotyped for rs6420424. Genotypes were in Hardy-
Weinberg equilibrium (HWE) as computed using Utility Programs
for Analysis of Genetic Linkage [46].
Table 1 shows genotype and allele frequencies for the three
BCMO1 SNPs and mean MPOD. Alleles were within reported
frequencies from other studies [26,39]. For example, this study
found a minor allele frequency (MAF) of 35% for rs11645428 and
Meyer’s et al. [26] found a MAF of 33%. Lietz et al. [39]
summarised allele frequencies of rs6420424 and rs6564851 from
different ethnic groups including their own cohort of 28 female
volunteers. They found a MAF of 45% for rs6420424 compared to
48% in our study and 48% for rs6564851 compared to 47% in our
study.
In the healthy group, there was a significant difference between
rs11645428 genotypes (F2,19 = 7.1, p,0.01) with the mean MPOD
values being on average lower for those with the GG genotype
(0.3860.2 D.U.) compared to those with the GA (0.5160.1 D.U.)
and the AA genotypes (0.7160.2 D.U.) (Figure 1). Post-hoc
analysis demonstrated that the rs11645428 GG genotype was
significantly lower compared to the AA genotype (p=0.002) and
that the GA genotype was significantly lower than the AA
genotype (p=0.05). There was also a significant difference
between the rs6420424 genotypes (F2,19 = 7.8, p,0.01) where
those with the GG genotype had higher MPOD levels compared
to those with the AA genotype. The average MPOD for the GG,
GA and AA genotypes were 0.6760.2 D.U., 0.4860.1 D.U. and
0.3360.2 D.U., respectively. Post-hoc analysis demonstrated that
participants with the GG genotype had significantly higher
MPOD levels compared to GA (p=0.03) and AA (p,0.01)
(Figure 2). Analysis of rs6564851 in healthy participants demon-
strated significant differences in mean MPOD (F2,19 = 15.5, p,
0.001), with the TT genotype showing significantly higher MPOD
(0.7260.2 D.U.), compared to the GT (0.4860.1 D.U.) and GG
(0.2960.2 D.U.) genotypes. Post-hoc analysis revealed that the TT
genotype was significantly higher than the GT and GG genotype
(p,0.01) (Figure 3).
In the patients with age-related macular degeneration there was
on average no significant difference in MPOD between the two
visits within the three months of anti-VEGF treatment (visit one:
mean MPOD=0.4760.1 D.U. and visit 2: mean
MPOD=0.4460.2 D.U., p=0.4). The average MPOD of these
two time points was taken for further analysis. There was no
significant difference in MPOD between the rs11645428 geno-
types (F2,22 = 0.4, p=0.7), the rs6420424 genotypes (F2,23 = 1.6,
p=0.2) or the rs6564851 genotypes (F2,22 = 1.0, p=0.3) in the
AMD patients. The average MPOD in the rs11645428 and
rs6420424 GG, GA and AA genotypes were 0.4760.2 D.U.,
0.4560.1 D.U., 0.3960.1 D.U. and 0.460.1 D.U., 0.4660.1
D.U., 0.5260.2 D.U., respectively. The average MPOD for the
rs6564851 TT, GT and GG genotypes was 0.3860.1 D.U.,
0.4660.1 D.U and 0.4860.2 D.U, respectively (Figure 1–3)
(Table 1).
We determined rs11645428, rs6420424 and rs6564851 ‘‘triple
genotypes’’ based on the previously reported BCMO1 beta-
carotene conversion efficiency, that is, those who should have
high- or low-conversion efficiency based on their BCMO1
genotypes [39]. Interestingly, the healthy participants MPOD
values reflected plasma conversion efficiency, with the GG/AA/
GG (rs11645428/rs6420424/rs6564851) low conversion triple
genotypes having low MPOD values, those with the AA/GG/TT
high conversion triple genotype had significantly higher MPOD
values while the remaining genotypes had intermediate MPOD
values (Figure 4). There was a significant difference between the
three high, low and intermediate MPOD groups (F2,16 = 6.8,
p=0.01). Data show that healthy persons with the AA/GG/TT
genotypes have on average significantly higher MPOD levels
(0.7260.2 D.U.) compared to those with the GG/AA/GG
genotypes (MPOD=0.2960.2 D.U.) (p,0.01). Those healthy
participants with the remaining genotypes showed significantly
higher MPOD (0.5860.2 D.U.) compared to the GG/AA/GG
genotype with the lowest MPOD (p=0.02) (Figure 4) (Table 2).
Discussion
The data demonstrate that BCMO1 SNPs and their predicted
effects on beta-carotene conversion efficiency in the plasma [39]
can be related to MPOD. We show that healthy participants fall
into high, low and intermediate MPOD values based on combined
BCMO1 rs11645428/rs6420424/rs6564851 genotypes. We dem-
onstrate that healthy participants with rs11645428 GG, rs6420424
AA and rs6564851 GG ‘‘low conversion’’ genotypes had also low
MPOD levels and that those with rs11645428 AA, rs6420424 GG
and rs6564851 TT ‘‘high conversion’’ genotypes had high MPOD
levels. All the remaining homozygous and heterozygous genotypes
had MPOD levels that were between the ‘‘high’’ and ‘‘low’’
conversion genotype groups. Hence the findings support our
hypothesis that the increased BCMO1 b-carotene conversion
efficiency in the plasma is reflected in increased MPOD and that
decreased conversion results in decreased MPOD.
The BCMO1 gene encodes an enzyme that cleaves b-
carotenoids to produce vitamin A. It has been hypothesised that
its reduced activity due to variants in the BCMO1 gene has an
effect on retinal levels of L and Z and that BCMO1 may modulate
concentration of lutein in the macula [27]. The mechanism by
which a change in enzymatic activity affects carotenoid uptake
however, is not clear. During et al. [47] suggested an antagonising
effect by showing differential absorption patterns of carotenoids in
Table 2. Genotype frequencies of BCMO1 triple genotypes
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a cellular in vitro model. Our findings suggest that decreased
conversion of b-carotene and hence increased b-carotene avail-
ability may cause competition with lutein uptake, thereby
decreasing MPOD. Conversely, increased b-carotene conversion
and reduced availability may improve uptake of macular pigments
in healthy humans.
In the cohort with age-related macular degeneration, MPOD
did not differ between genotypes or triple genotypes. This is
consistent with our hypothesis and suggests that other factors may
be involved. In particular, in advanced AMD where there is a
change in retinal anatomy, retinal carotenoid binding proteins
[48,49,50] may be altered, hence affecting MPOD. Additional
environment and genetic factors are influential in the evolution of
AMD and while macular pigments may protect from environ-
mental risk, this function may be ‘‘overridden’’ by a strong genetic
predisposition for AMD. All our patients had advanced neovas-
cular AMD and macular pigment was not a protective factor in
this cohort. Complement factor H (CFH) genotypes have been
identified as major contributors to the risk of developing AMD
[51,52] and we found that the AMD patients with the homozygous
CFH high risk genotype had on average lower MPOD (0.4360.1
D.U.) compared to the low risk genotypes (0.4760.1 D.U) (data
not shown, p=0.2). This is in support of another study that
demonstrated reduced macular pigment in a small cohort of
healthy participants who were homozygous for CFH risk genotypes
[53]. Our findings are further supported by a recent large study in
women that investigated the relationship of BCMO1 genotypes
with macular pigment optical density in a sample of patients who
predominantly had early AMD [54]. While Meyers et al. [54] did
not investigate combined BCMO1 genotypes as done in this study,
they demonstrated a relationship between MPOD and one of the
BCMO1 genotypes we investigated. The strongest relationship
however, was found between MPOD and other genes related to
carotenoid status (ABCA1, ALDH3A2 and BCO2) [54]. Meyers
et al. [54] acknowledge that carotenoid pathway genes need to be
evaluated in relation to early and advanced AMD risk in
prospective studies. Our study therefore provides evidence of a
differing impact of BCMO1 genotypes on MPOD based on AMD
stage.
Another finding was that repeated anti-VEGF treatment did not
affect MPOD levels over a short period of three months. Anti-
VEGF therapy can cause toxic photoreceptor damage [55], and
macular pigment can be found in outer photoreceptor segments.
The effect of anti-VEGF on MPOD however, is unknown and
studies have only considered the effects of laser treatment on
MPOD [29]. Our findings may have importance for recovery of
vision in patients undergoing anti-VEGF treatment given the role
of macular pigment in visual performance with studies demon-
strating that macular pigments enhance contrast sensitivity,
chromatic discrimination and mesopic visual function [2,5,6,56].
However, it remains to be shown whether supplementation of
macular pigments is useful in advanced AMD for improvement of
visual function rather than protection, in particular when
considering that the retinal uptake of pigments may be affected.
Our study reflects emerging evidence of the significant effect of
gene variants modifying MPOD levels and that this effect may be
different in patients with retinal disease. Our study confirms large
association studies of BCMO1 gene variants with MPOD in
healthy participants [26] [28]. It is known that these SNPs are
associated with high or low serum beta-carotene levels [39] but
none of these studies investigated the combined effects of these
SNPs on MPOD. Also, these effects were not evaluated in different
cohorts with and without AMD. Additionally, our study suggests
that competitive uptake of carotenoids requires further assessment
in different population cohorts with and without retinal disease.
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